BFRIW — Biofrontera Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1858685 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 10,084,000 | 7,968,000 | -3,928,000 | -4,752,000 | 24,787,000 | 6,317,000 | 18,717,000 |
| Dec 2025 | 17,100,000 | 14,091,000 | 4,559,000 | 5,640,000 | 28,564,000 | 6,392,000 | 18,084,000 |
| Sep 2025 | 6,988,000 | 4,943,000 | -6,278,000 | -6,649,000 | 15,415,000 | 3,417,000 | 17,996,000 |
| Jun 2025 | 9,030,000 | 6,388,000 | -5,079,000 | -5,324,000 | 20,142,000 | 7,239,000 | 24,810,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,314,000
Investing CF
$2,996,000
Financing CF
$10,850,000
CapEx
$-10,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-132,697,000
Inventory
$1,231,000
Receivables
$3,879,000
ST Investments
$9,000
EBIT TTM
$-10,245,000
Pretax Income TTM
$-11,058,000
Interest Exp TTM
$401,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$46,175,000
EBITDA
$-5,968,000
Free Cash Flow
$-7,597,750
Enterprise Value
—
Total Cash
$4,667,000
Total Debt
$7,504,000
Shares Out
—
Trailing EPS
$-1.30
Book Value
$0.42
ROE
-988.4%
ROA
-17.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 41,705,000 | -11,348,000 | -10,536,000 | 28,564,000 | 18,084,000 | — | -13,361,000 |
| Dec 2024 | 37,321,000 | -17,210,000 | -17,759,000 | 22,101,000 | 17,668,000 | — | -10,270,000 |
| Dec 2023 | 34,071,000 | -22,577,000 | -20,131,000 | 27,932,000 | 23,139,000 | — | -24,895,000 |
| Dec 2022 | 28,674,000 | -22,381,000 | -640,000 | 50,884,000 | 27,006,000 | — | -16,199,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.11T | $1246.93 | — |
| JNJ | JOHNSON & JOHNSON | $658.00B | $273.04 | — |
| ABBV | AbbVie Inc. | $467.44B | $264.52 | — |
| MRK | Merck & Co., Inc. | $371.70B | $150.66 | — |
| NVSEF | NOVARTIS AG | $310.96B | $163.60 | — |
News headlines (Yahoo Finance, 1h cache)
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
2026-05-21 13:15 · Yahoo
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
2026-05-13 13:00 · Yahoo
Biofrontera (BFRI) Q2 2026 Earnings Call Transcript
2026-08-20 15:58 · Yahoo
Biofrontera Inc. Q2 2026 Earnings Call Summary
2026-08-14 12:30 · Yahoo
Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ...
2026-08-13 23:03 · Yahoo
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates
2026-08-13 14:10 · Yahoo
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
2026-08-13 12:51 · Yahoo
BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates
2026-08-12 21:40 · Yahoo
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
2026-08-05 20:15 · Yahoo
Biofrontera (BFRI) Q1 2026 Earnings Transcript
2026-06-02 17:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.